- Conditions: Urinary Incontinence; Multiple Sclerosis
Interventions: Biological: OnabotulinumtoxinA; Drug: Placebo (Normal Saline); OnabotulinumtoxinA
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Condition: Facial Rhytides
Intervention:
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Intervention: Drug: Bimatoprost 0.01%
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Intervention: Drug: Lumigan® 0.01%
Sponsors: Allergan; Allergan
Recruiting - verified April 2012 - Conditions: Low Anterior Resection Syndrome; Rectal Cancer
Intervention: Drug: intra-rectal Botulinum toxin A injection
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Allergan
Not yet recruiting - verified June 2011 - Condition: Idiopathic Toe-walking
Intervention: Drug: Botulinum toxin A
Sponsors: Karolinska Institutet; Karolinska Institutet
Completed - verified May 2012 - Condition: Retinal Vein Occlusion
Intervention: Drug: Dexamethasone with rescue ranibizumab
Sponsors: Wills Eye; Wills Eye
Not yet recruiting - verified April 2012 - Condition: Lip Volume Enhancement
Interventions: Device: Juvéderm® Volbella with Lidocaine; Device: Restylane-L®
Sponsors: Allergan Medical; Allergan Medical
Recruiting - verified April 2012 - Conditions: Rosacea; Erythema
Interventions: Drug: AGN-199201 Formulation A and B; Drug: AGN-199201 Formulation B and C; Drug: AGN-199201 Formulation C and A; Drug: AGN-199201 Formulatio A and AGN-199201 Vehicle; Drug: AGN-199201 Formulation B and AGN-199201 Vehicle; Drug: AGN-199201 Formulation C and AGN-199201 Vehicle; Drug: AGN-199201 Formulation A; Drug: AGN-199201 Formulation B; Drug: AGN-199201 Formulation C; Drug: AGN-199201 Vehicle
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Condition: Muscle Spasticity
Interventions: Biological: botulinum toxin Type A; Drug: Normal Saline (Placebo) Followed by botulinum toxin Type A
Sponsors: Allergan; Allergan
Recruiting - verified April 2012 - Conditions: Macular Edema; Retinal Vein Occlusion
Intervention: Drug: dexamethasone 700 ug intravitreal implant
Sponsors: Allergan; Allergan
Recruiting - verified April 2012 - Conditions: Open-Angle Glaucoma; Ocular Hypertension
Intervention: Drug: Bimatoprost 0.01% ophthalmic solution
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Conditions: Retinal Vein Occlusion; Macular Edema
Intervention: Drug: Dexamethasone intravitreal implant
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Conditions: Retinal Vein Occlusion; Macular Oedema
Intervention: Drug: dexamethasone intravitreal implant 0.7 mg
Sponsors: Allergan; Allergan
Recruiting - verified April 2012 - Conditions: Diabetic Macular Edema.; Non-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy
Interventions: Drug: dexamethasone intravitreal implant; Drug: intravitreal bevacizumab
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Condition: Age-related Volume Deficit in the Mid-face
Intervention: Device: Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)
Sponsors: Allergan Medical; Allergan Medical
Recruiting - verified March 2012 - Conditions: Macular Edema, Cystoid; Vision Disorders; Diabetic Macular Edema; Cystoid Macular Edema Following Cataract Surgery; Cataract
Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex); Procedure: Cataract surgery
Sponsors: Postgraduate Institute of Medical Education and Research; Postgraduate Institute of Medical Education and Research
Recruiting - verified March 2012 - Condition: Morbid Obesity
Interventions: Device: Standard Laparoscopic Adjustable Gastric Band Surgery; Device: Plicated Laparoscopic Adjustable Gastric Band Surgery
Sponsors: Duke University; Duke University; Allergan
Not yet recruiting - verified April 2012 - Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Intervention:
Sponsors: Allergan; Allergan
Recruiting - verified February 2012 - Conditions: Retinal Vein Occlusion; Macular Edema; Uveitis, Posterior
Intervention: Drug: dexamethasone 700 μg intravitreal implant
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Condition: Contact Lens Related Dry Eye Syndrome
Interventions: Device: OPTIVEtm Plus; Procedure: No treatment; Device: Blink Contacts® Eye Drops
Sponsors: Optometric Technology Group Ltd; Optometric Technology Group Ltd; Allergan
Recruiting - verified February 2012 - Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Interventions: Drug: travoprost 0.004% then bimatoprost 0.01%; Drug: travoprost 0.004% then travoprost 0.004%/timolol 0.5% combination
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Condition: Cystoid Macular Edema Following Cataract Surgery, Bilateral
Intervention: Drug: Ketorolac Tromethamine
Sponsors: University of Campinas, Brazil; University of Campinas, Brazil
Recruiting - verified February 2012 - Conditions: Glaucoma; Ocular Hypertension
Interventions: Drug: 0.1% brimonidine tartrate and 0.01% bimatoprost; Drug: 0.01% bimatoprost and 0.2% hypromellose
Sponsors: Allergan; Allergan
Recruiting - verified January 2012 - Condition: Osteoarthritis
Interventions: Biological: botulinum toxin Type A; Drug: Normal Saline (Placebo)
Sponsors: Allergan; Allergan
Recruiting - verified January 2012 - Condition: Health
Intervention: Other: No treatment
Sponsors: Allergan; Allergan
Completed - verified May 2012 - Condition: Migraine Disorders
Intervention: Biological: onabotulinumtoxinA
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Condition: Refractory Urge Urinary Incontinence
Interventions: Device: InterStim® device; Drug: Botox® injection
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Duke University; University of Alabama at Birmingham; University of California, San Diego; The Cleveland Clinic; Brown University; University of New Mexico; University of Pennsylvania; University of Pittsburgh; Oregon Health and Science University; RTI International
Recruiting - verified February 2012 - Condition: Hallux Valgus
Interventions: Drug: BOTOX; Drug: Normal Saline (0.9% NaCl)
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; National Science Council, Taiwan
Recruiting - verified March 2010 - Condition: Macular Edema
Interventions: Drug: dexamethasone Intravitreal Implant; Drug: ranibizumab
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Intervention: Drug: bimatoprost 0.01% ophthalmic solution
Sponsors: Allergan; Allergan
Recruiting - verified December 2011 - Conditions: Sialorrhea; Cerebral Palsy
Intervention: Biological: BOTULINUM NEUROTOXIN TYPE-A
Sponsors: Hospital Vall d'Hebron; Hospital Vall d'Hebron; Allergan
Recruiting - verified December 2011 - Condition: Conjunctivitis, Allergic
Interventions: Drug: alcaftadine 0.25% ophthalmic solution (LASTACAFT™); Drug: olopatadine 0.2% Ophthalmic Solution (Pataday™); Drug: hydroxypropyl methylcellulose 0.3% Ophthalmic Solution (Placebo)
Sponsors: Allergan; Allergan
Completed - verified March 2012 - Conditions: Macular Edema; Cystoid Macular Edema; Uveal Melanoma; Radiation Maculopathy; Radiation Retinopathy
Intervention: Drug: Ozurdex (Dexamethasone intravitreal implant )
Sponsors: Wills Eye; Arman Mashayekhi; Allergan
Not yet recruiting - verified November 2011 - Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified May 2012 - Condition: Dry Eye Syndromes
Interventions: Drug: Eye Drop Formulation A; Drug: Eye Drop Formulation B; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops; Drug: Carboxymethylcellulose Based Lubricant Eye Drops
Sponsors: Allergan; Allergan
Completed - verified March 2012 - Condition: Hypotrichosis
Interventions: Drug: bimatoprost ophthalmic solution 0.03%; Drug: bimatoprost vehicle solution
Sponsors: Allergan; Allergan
Active, not recruiting - verified April 2012 - Conditions: Obesity; Morbid Obesity
Interventions: Device: abiliti system implant; Device: Laparoscopic adjustable gastric band (Allergan Lap Band)
Sponsors: IntraPace, Inc; IntraPace, Inc
Recruiting - verified October 2011 - Condition: Dry Eyes
Intervention:
Sponsors: COA Research Foundation, INC; COA Research Foundation, INC; Allergan
Recruiting - verified January 2012 - Condition: Macular Edema
Intervention: Drug: Dexamethasone intravitreal implant 0.7 mg
Sponsors: Allergan; Allergan
Completed - verified April 2012 - Conditions: Retinal Vein Occlusion; Macular Edema
Interventions: Drug: Ozurdex; Drug: Ozurdex
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Conditions: Cerebral Palsy; Post-operative Pain
Intervention: Drug: botulinum toxin intramuscular injection
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust
Recruiting - verified March 2012 - Conditions: Cataract; Dry Eye
Intervention:
Sponsors: Ophthalmic Consultants of Long Island; Ophthalmic Consultants of Long Island; Allergan
Recruiting - verified September 2011 - Condition: Migraine Disorders
Intervention: Biological: botulinum toxin Type A
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Condition: Scar
Interventions: Drug: Botulinum Toxin Type A; Drug: Botulinum Type A; Drug: Normal Saline; Drug: Normal Saline
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
Recruiting - verified August 2011 - Conditions: Retinal Vein Occlusion; Macular Edema
Interventions: Drug: dexamethasone intravitreal implant (Ozurdex®); Biological: ranibizumab (Lucentis®)
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Condition: Glaucoma
Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution
Sponsors: Allergan; Allergan
Recruiting - verified November 2011 - Condition: Acne Vulgaris
Interventions: Drug: Fixed Combination dapsone/adapalene Formulation A Gel; Drug: Fixed Combination dapsone/adapalene Formulation B Gel; Drug: dapsone 5% gel; Drug: adapalene 0.3% gel
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Conditions: Parkinson's Disease; Neurogenic Bladder; Urinary Incontinence; Clostridium Botulinum Toxin Adverse Reaction
Intervention: Drug: Cystoscopic injection of Botox into the urinary bladder
Sponsors: Stanford University; Stanford University; Allergan
Completed - verified August 2011 - Condition: Stroke With Hemiparesis
Intervention: Drug: Botulinum Toxin commonly known as BOTOX®
Sponsors: New York University School of Medicine; New York University School of Medicine; Allergan
Recruiting - verified April 2012 - Condition: Healthy Volunteers
Intervention:
Sponsors: Allergan; Allergan
Completed - verified October 2011 - Conditions: Retinal Vein Occlusion; Macular Edema
Intervention: Other: No treatment
Sponsors: Allergan; Allergan
Completed - verified March 2012 - Condition: Obesity
Intervention: Device: LAP-BAND (Allergan, Inc.)
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified April 2012 - Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012 - Condition: Age-related Macular Degeneration
Interventions: Drug: AGN-150998; Drug: AGN-150998; Drug: AGN-150998; Drug: AGN-150998; Drug: AGN-150998; Drug: AGN-150998; Drug: ranibizumab
Sponsors: Allergan; Allergan
Recruiting - verified January 2012 - Conditions: Epiretinal Membrane; Macular Edema
Intervention: Drug: Dexamethasone Intravtireal Implant
Sponsors: Barnes Retina Institute; Barnes Retina Institute; Allergan
Recruiting - verified April 2012 - Condition: Mumps
Intervention: Drug: Botulinum Toxin Type A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified August 2011 - Condition: Eyelash Hypotrichosis
Interventions: Drug: bimatoprost solution 0.03%; Drug: bimatoprost vehicle solution
Sponsors: Allergan; Allergan
Active, not recruiting - verified January 2012 - Condition: Eyelash Hypotrichosis
Interventions: Drug: bimatoprost solution 0.03%; Drug: bimatoprost vehicle solution
Sponsors: Allergan; Allergan
Active, not recruiting - verified January 2012 - Condition: Glabellar Frown Lines
Interventions: Biological: botulinum toxin Type A; Drug: Normal Saline
Sponsors: Allergan; Allergan
Completed - verified January 2012 - Conditions: Facial Rhytides; Glabellar Frown Lines
Interventions: Biological: botulinum toxin Type A (30 Units); Biological: botulinum toxin Type A (40 Units); Drug: Normal Saline
Sponsors: Allergan; Allergan
Completed - verified April 2012 - Condition: Depression
Interventions: Drug: Clostridium botulinum toxin type A neurotoxin complex; Other: 0.9% NaCl solution
Sponsors: Seton Family of Hospitals; Seton Family of Hospitals
Recruiting - verified May 2012 - Condition: Muscle Spasticity
Intervention: Biological: botulinum toxin Type A
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Condition: Soft Tissue Support and Repair
Intervention: Device: SeriScaffold™ Surgical Scaffold
Sponsors: Allergan Medical; Allergan Medical
Enrolling by invitation - verified December 2011 - Condition: Muscle Spasticity
Intervention: Other: No treatment
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Condition: Allergic Conjunctivitis
Intervention: Drug: alacaftadine and naphazoline HCl & pheniramine maleate
Sponsors: Hom, Milton M., OD, FAAO; Hom, Milton M., OD, FAAO; Allergan
Enrolling by invitation - verified July 2011 - Condition: Torticollis
Intervention: Biological: botulinum toxin Type A
Sponsors: Allergan; Allergan
Completed - verified June 2011 - Condition: Hypotrichosis
Intervention: Drug: topical bimatoprost
Sponsors: Beer, Kenneth R., M.D., PA; Kenneth Beer; Allergan
Active, not recruiting - verified January 2012 - Condition: Dry Eye
Interventions: Drug: Next Generation Emulsion; Drug: Refresh Dry Eye Therapy; Drug: Refresh Contacts
Sponsors: Glasgow Caledonian University; Glasgow Caledonian University; Allergan
Not yet recruiting - verified February 2011 - Conditions: Dystonia; Voice Disorders
Intervention:
Sponsors: Emory University; Hyder A. Jinnah, MD, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Office of Rare Diseases (ORD); Allergan; Dystonia Study Group
Recruiting - verified March 2012
 |
Allergan - Database of Clinical Trials by Pharmaceutical Companies |
